SCHEMBL17542065

SCHEMBL17542065

CC(C)(C)OC(=O)N1CC(C(F)(F)c2ccc(NC(=O)c3ccc(Cl)cc3)cc2)C1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ MAPT P10636 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ NR3C1 P04150 3/20 0.45
▸ HTT P42858 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ USP30 Q70CQ3 2/20 0.44
▸ ENPP3 O14638 2/20 0.43
▸ ENPP1 P22413 2/20 0.43
▸ ENPP2 Q13822 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.43
▸ RHOC P08134 1/20 0.43
▸ RHOA P61586 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23234102 0.84 NPC1 (0.52) SMN1; SMN2NPC1RAB9AKMT2AENPP3
SCHEMBL17542185 0.82 MEN1 (0.60) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL1990469 0.81 USP30 (0.49) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL29538387 0.80 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL1989607 0.80 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL17729471 0.79 MAPT (0.52) MAPTUSP30
SCHEMBL502899 0.78 TP53 (0.59) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL502898 0.78 TP53 (0.59) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL17541957 0.77 RORC (0.49) MAPTUSP30
SCHEMBL20570727 0.77 RORC (0.49) MAPTUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3186224-B1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS HOFFMANN LA ROCHE (CH) 2021-04-21 — — EP disclosed
CN-107001259-B Substituted azetidine derivatives as TAAR ligands 豪夫迈·罗氏有限公司 2019-12-06 — — CN disclosed
US-10023559-B2 Substituted azetidine derivatives HOFFMAN-LA ROCHE INC. (US) 2018-07-17 — — US disclosed
EP-3186224-A1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS F. Hoffmann-La Roche AG (CH) 2017-07-05 — — EP disclosed
US-20170144994-A1 SUBSTITUTED AZETIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-05-25 — — US disclosed
WO-2016030310-A1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2016-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023559-B2 Substituted azetidine derivatives HTR1B, MTNR1B, DRD2 SMN1; SMN2 1381/4885NPC1 214/4885RAB9A 210/4885
US-20170144994-A1 SUBSTITUTED AZETIDINE DERIVATIVES HTR1B, MTNR1B, DRD2 SMN1; SMN2 1381/4885NPC1 214/4885RAB9A 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback